Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI ChemoCentryx, Inc. daily Stock Chart
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own0.70% Shs Outstand49.74M Perf Week-0.12%
Market Cap414.83M Forward P/E- EPS next Y-1.06 Insider Trans-0.64% Shs Float28.79M Perf Month47.09%
Income-29.50M PEG- EPS next Q-0.20 Inst Own50.20% Short Float6.53% Perf Quarter8.03%
Sales31.10M P/S13.34 EPS this Y20.10% Inst Trans0.01% Short Ratio14.42 Perf Half Y-15.07%
Book/sh0.77 P/B10.83 EPS next Y-63.10% ROA-20.40% Target Price13.00 Perf Year7.34%
Cash/sh2.42 P/C3.44 EPS next 5Y- ROE-67.60% 52W Range5.42 - 10.80 Perf YTD40.17%
Dividend- P/FCF- EPS past 5Y-45.70% ROI- 52W High-24.41% Beta1.60
Dividend %- Quick Ratio2.80 Sales past 5Y-17.70% Gross Margin- 52W Low50.55% ATR0.56
Employees62 Current Ratio2.80 Sales Q/Q109.30% Oper. Margin-99.10% RSI (14)59.57 Volatility7.43% 7.31%
OptionableYes Debt/Eq0.00 EPS Q/Q8.80% Profit Margin-94.80% Rel Volume1.57 Prev Close8.34
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume130.25K Price8.16
Recom2.30 SMA2016.32% SMA5019.17% SMA2008.30% Volume204,172 Change-2.16%
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
Jan-08-18 08:30AM  ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer GlobeNewswire
Jan-06-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-04-18 12:11PM  Here's Why ChemoCentryx Rose as Much as 53.5% Today Motley Fool +39.42%
07:05AM  ChemoCentryx Secures up to $100 Million in New Capital Commitments GlobeNewswire
07:00AM  Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency GlobeNewswire
01:00AM  AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY GlobeNewswire
Jan-03-18 08:30AM  ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:55AM  ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017 Capital Cube +6.49%
Dec-27-17 08:41AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Nov-27-17 05:30PM  Should You Buy ChemoCentryx Inc (CCXI) Now? Simply Wall St.
Nov-18-17 08:56AM  Edited Transcript of CCXI earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-17-17 08:30AM  ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-10-17 01:06PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : November 10, 2017 Capital Cube
Nov-09-17 12:18PM  ETFs with exposure to ChemoCentryx, Inc. : November 9, 2017 Capital Cube
07:20AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : November 9, 2017 Capital Cube
Nov-07-17 05:49PM  ChemoCentryx reports 3Q loss Associated Press
04:40PM  ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Nov-03-17 08:31AM  Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Nov-01-17 08:30AM  ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017 GlobeNewswire
Oct-20-17 08:26AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : October 20, 2017 Capital Cube
Oct-16-17 09:49AM  ETFs with exposure to ChemoCentryx, Inc. : October 16, 2017 Capital Cube
Oct-05-17 10:55AM  ETFs with exposure to ChemoCentryx, Inc. : October 5, 2017 Capital Cube
Oct-04-17 09:21AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube
Oct-03-17 08:14AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : October 3, 2017 Capital Cube
Oct-02-17 05:27PM  All You Need To Know About ChemoCentryx Incs (CCXI) Risks Simply Wall St. +6.87%
Sep-15-17 08:37PM  Is There Now An Opportunity In ChemoCentryx Inc (CCXI)? Simply Wall St.
Sep-05-17 08:30AM  ChemoCentryx to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-21-17 05:55PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : August 21, 2017 Capital Cube
Aug-14-17 02:11AM  Edited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:38AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017 Capital Cube -5.61%
01:07AM  ChemoCentryx reports 2Q loss Associated Press
Aug-08-17 04:05PM  ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
01:10PM  Investor Network: Chemocentryx, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 08:30AM  ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017 GlobeNewswire
Jul-18-17 07:29AM  New Strong Buy Stocks for July 18th Zacks
Jul-12-17 08:15AM  ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4% Zacks +5.18%
Jun-15-17 01:27PM  ETFs with exposure to ChemoCentryx, Inc. : June 15, 2017 Capital Cube
Jun-08-17 08:07AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : June 8, 2017 Capital Cube
Jun-06-17 07:30AM  Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
May-24-17 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
May-23-17 08:30AM  ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) GlobeNewswire
May-16-17 01:10PM  Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-15-17 05:07PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : May 15, 2017 Capital Cube
May-12-17 08:15AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : May 12, 2017 Capital Cube
May-11-17 08:51PM  Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.21%
May-10-17 04:50PM  ChemoCentryx reports 1Q loss Associated Press
04:05PM  ChemoCentryx Reports First Quarter 2017 Financial Results GlobeNewswire
11:30AM  Investor Network: Chemocentryx, Inc. to Host Earnings Call Accesswire
Apr-27-17 08:30AM  ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017 GlobeNewswire
Apr-06-17 08:27AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : April 6, 2017 Capital Cube
Mar-24-17 08:14AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : March 24, 2017
Mar-22-17 08:30AM  ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) GlobeNewswire
Mar-18-17 01:04PM  CHEMOCENTRYX, INC. Financials
Mar-17-17 10:11AM  ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Zacks
Mar-15-17 03:04PM  Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT Thomson Reuters StreetEvents +9.27%
Mar-14-17 05:00PM  ChemoCentryx reports 4Q loss Associated Press
04:32PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 ChemoCentryx Inc Earnings Release - After Market Close
Mar-10-17 09:29AM  Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix TheStreet.com
Mar-03-17 10:10AM  Sio Capital Remains Bullish On These Stocks Despite Weak Performance Insider Monkey
Mar-02-17 04:32PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-01-17 08:30AM  ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017 GlobeNewswire
Feb-28-17 08:30AM  ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-21-17 08:16AM  Coverage initiated on ChemoCentryx by JMP Securities
Feb-14-17 04:18PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases GlobeNewswire
Jan-20-17 03:30PM  ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer GlobeNewswire
10:00AM  ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco GlobeNewswire
Jan-19-17 07:35AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19, 2017
Jan-09-17 07:30AM  ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases GlobeNewswire
Jan-04-17 08:30AM  ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 10:21AM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : January 3, 2017 +5.68%
Jan-02-17 08:12AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2, 2017
Dec-22-16 01:59PM  ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases -5.74%
12:46PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
12:30PM  Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases GlobeNewswire
Dec-16-16 12:52AM  Is ChemoCentryx Inc (CCXI) A Stock Worth Buying? at Insider Monkey +9.49%
Nov-16-16 02:45PM  Everyday Health Inc (EVDY), ANSYS, Inc. (ANSS), More: Why You Should Pay Attention To These Stocks at Insider Monkey
Nov-08-16 03:49PM  CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report
11:39AM  Edited Transcript of CCXI earnings conference call or presentation 7-Nov-16 10:00pm GMT
Nov-07-16 06:01PM  ChemoCentryx reports 3Q loss +8.56%
05:26PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  ChemoCentryx Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
08:30AM  ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (CLEAR and CLASSIC) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (Avacopan) GlobeNewswire
07:07AM  Q3 2016 ChemoCentryx Inc Earnings Release - After Market Close
Oct-28-16 08:30AM  ChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7, 2016 GlobeNewswire
Oct-27-16 08:30AM  ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy GlobeNewswire
Oct-25-16 04:03PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Oct-20-16 12:05PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial +5.02%
08:30AM  ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors GlobeNewswire
Oct-18-16 08:30AM  ChemoCentryxs CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models GlobeNewswire +6.02%
Oct-17-16 08:30AM  ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome (aHUS) at ASN Kidney Week 2016 GlobeNewswire
Sep-27-16 07:00AM  Healthcare-Focused Michael Castor Added These Stocks to His Portfolio Last Quarter at Insider Monkey +11.81%
Sep-01-16 04:05PM  ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer GlobeNewswire +5.80%
Aug-25-16 08:30AM  ChemoCentryx to Present at the Baird 2016 Global Healthcare Conference GlobeNewswire
Aug-09-16 03:03PM  Edited Transcript of CCXI earnings conference call or presentation 8-Aug-16 9:00pm GMT
01:47PM  CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report
Aug-08-16 07:31PM  ChemoCentryx reports 2Q loss
04:32PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn??s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schall Thomas J.President and CEOJan 01Option Exercise0.0066,66602,221,711Jan 03 07:47 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0033,333057,184Jan 03 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0018,333034,724Jan 03 07:31 PM
SINGH RAJINDERSVP, ResearchJan 01Option Exercise0.0010,000010,000Jan 03 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Oct 20Option Exercise0.0033,333042,610Oct 24 05:21 PM
LUCAS ROGER CDirectorAug 01Sale10.072,25022,66793,846Aug 03 06:11 PM
Edwards Thomas A.DirectorJul 28Option Exercise0.006,7670138,785Aug 01 06:17 PM
Bekker PetrusChief Medical OfficerJul 13Option Exercise7.9316,013126,90971,964Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 13Sale10.2116,013163,46459,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 12Option Exercise6.7330,000201,87469,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 12Sale9.9830,000299,28059,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 11Option Exercise6.7830,000203,32683,715Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 11Sale9.7830,000293,32659,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 10Option Exercise6.302901,82760,129Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 10Sale9.302902,69759,839Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 07Option Exercise6.3019,587123,39879,426Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 07Sale9.3019,587182,15959,839Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJun 30Option Exercise6.6230,000198,59377,848Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 30Sale9.2330,000276,87059,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 29Option Exercise7.105,50939,11465,348Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 29Sale9.115,50950,16759,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 28Option Exercise7.1030,000213,00089,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 28Sale9.1230,000273,66959,839Jun 30 07:32 PM
FECZKO JOSEPH MDirectorMay 26Option Exercise0.0020,362069,184May 30 07:37 PM
Parker Geoffrey M.DirectorMay 26Option Exercise0.0020,362045,671May 30 07:28 PM
Edwards Thomas A.DirectorMay 26Option Exercise0.0020,3620132,018May 30 07:24 PM
LUCAS ROGER CDirectorMay 26Option Exercise0.0020,362096,096May 30 07:18 PM
Tyree James LDirectorMay 26Option Exercise0.0020,362053,849May 30 07:02 PM
LUCAS ROGER CDirectorMay 01Sale7.314,00029,22862,822May 03 07:06 PM
LUCAS ROGER CDirectorFeb 01Sale7.324,00029,29066,822Feb 03 05:42 PM